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Precis 35 
Colposcopy following positive high-risk human papillomavirus testing maintained sensitivity and 36 
improved positive predictive value of high-grade cervical dysplasia among women living with human 37 
immunodeficiency virus.  38 
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Abstract 39 
Objective: To evaluate the performance of cervical cancer screening algorithms for women living with 40 
human immunodeficiency virus (HIV), utilizing primary high-risk human papillomavirus testing (hrHPV) 41 
testing followed by cytology, visual inspection with acetic acid (VIA), or colposcopy. 42 
Methods: Prospective cohort study of women living with HIV in Botswana. All participants underwent 43 
hrHPV testing. Participants with positive hrHPV results underwent cytology, VIA, colposcopy, and 44 
biopsy. Participants with negative hrHPV results also underwent cytology. Histopathology was the 45 
reference standard for determination of pre-invasive cervical disease and cervical cancer. Sensitivity, 46 
specificity, positive predictive value (PPV), negative predictive value (NPV) and likelihood ratios (LR) of 47 
hrHPV-based two-stage screening algorithms were calculated.  48 
Results: Among 300 women screened, 88 (29%) had a positive hrHPV test, and 29 of the 88 (35%) 49 
hrHPV-positive women had CIN2+ on histopathology. hrHPV followed by colposcopy resulted in a 50 
sensitivity of 83%, specificity of 49%, PPV of 47%, LR+ of +1.6 and LR- of -0.4. hrHPV followed by 51 
VIA resulted in a reduced sensitivity of 59%, specificity of 49%, PPV of 39%, LR+ of +1.2 and LR- of -52 
0.8. hrHPV testing followed by cytology also resulted in a reduced sensitivity of 62%, specificity of 77%, 53 
PPV of 60%, LR+ of +2.7 and LR- of -0.5. Stratification by HPV 16/18/45 did not improve performance 54 
of the algorithms. 55 
Conclusion: In a high-risk HIV population, hrHPV testing followed by colposcopy demonstrated the 56 
highest sensitivity and PPV in detecting high-grade cervical dysplasia. Allocating resources to colposcopy 57 
in resource-limited settings may be more effective than other screening strategies. 58 
Clinical Trial Registration: 2-stage Cervical Cancer Screening in Botswana,  59 
https://clinicaltrials.gov/ct2/show/NCT03324009, NCT03324009  60 
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Introduction 61 
Cervical cancer is the fourth leading cause of cancer death in women worldwide and the leading cause of 62 
cancer death in women in Botswana.1,2,3 The disease burden in Botswana is impacted by the high prevalence 63 
of human immunodeficiency virus (HIV), which is 22% among people aged 15-49 years and is a well-64 
established risk factor for cervical cancer.4,5,6 Most cervical cancers are associated with infection with high-65 
risk human papillomavirus (hrHPV) types.7,8,9 Globally, HPV prevalence is variable, ranging from 15-45%, 66 
with higher prevalence in women living with HIV.10,11,12 HPV 16, 18, and 45 are the high-risk types most 67 
commonly associated with cervical cancer in Africa.13,14,15 Among women living with HIV, persistent 68 
hrHPV positivity and infection with multiple types are strong risk factors for cervical cancer.16  69 
Cervical cancer is largely preventable and treatable where screening and treatment programs are 70 
available.17,18,19,20  Cervical cancer screening strategies are most effective when based on local evidence and 71 
tailored to the population and resource infrastructure. 21  Current programming in Botswana utilizes a 72 
combination of cytology (Pap smear) and visual inspection with acetic acid (VIA). However, there is 73 
mounting evidence that primary hrHPV testing is the most effective screening strategy because of its high 74 
sensitivity (95%).22  hrHPV testing is increasingly included in some national guidelines.23, 24,25  hrHPV 75 
testing is planned for future national programming in Botswana, but the guidelines for managing positive 76 
hrHPV results remain unclear, particularly among women living with HIV.26,27,28 Appropriate triage of a 77 
positive hrHPV result is necessary to prevent overtreatment of hrHPV when it is associated with no or low-78 
grade cervical dysplasia. The best two-stage screening strategy is unknown for women living with HIV in 79 
resource-limited settings29,30, 34  80 
In this study, we investigated the performance of primary hrHPV testing followed by cytology, VIA and 81 
colposcopy impression to predict pre-invasive cervical disease in women living with HIV in Botswana. We 82 
hypothesized that VIA, cytology and colposcopy would perform similarly as a triage test in women living 83 
with HIV who test positive for hrHPV. Evaluating cervical cancer screening algorithms with primary 84 
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hrHPV testing in women living with HIV is essential for establishing an evidence-based screening strategy 85 
in this high-risk population. 86 
 87 
Methods 88 
We conducted a prospective cohort study of women seeking care at the infectious disease care clinic at 89 
Princess Marina Hospital in Gaborone, Botswana. The infectious disease care clinic provides care to 90 
people living with HIV at Princess Marina Hospital, the regional tertiary referral hospital. Women 91 
included in the study were HIV-positive, greater than 24 years of age, and competent to understand study 92 
procedures and give informed consent. Women were excluded if they were currently pregnant, currently 93 
menstruating heavily or with persistent vaginal discharge, had a previous hysterectomy, or had a previous 94 
diagnosis of cervical cancer. 95 
Eligible women were provided study information by a research assistant or study nurse while waiting for 96 
their scheduled clinical visit at infectious disease care clinic and offered voluntary participation. After 97 
obtaining informed consent, we administered a questionnaire including demographic data, HIV treatment 98 
history, history of cervical cancer screening, and knowledge about cervical cancer. In addition to patient 99 
report, the electronic medical record was searched for results of prior cervical cancer screening. The 100 
institutional review boards of the Botswana Ministry of Health and Wellness, the University of Botswana, 101 
and the Beth Israel Deaconess Medical Center approved this study. The ethics committee of Princess 102 
Marina Hospital also approved this study. 103 
All participants underwent a speculum examination of the cervix by a trained study nurse, at which time 104 
samples were collected from the cervix for hrHPV testing and for cervical cytology using a Cervex-brush. 105 
HPV specimens were placed in a PreservCyt transport medium and testing was performed using the Xpert 106 
HPV Assay (Cepheid, Sunnyvale, CA) at the Botswana Harvard AIDS Initiative Partnership Laboratory. 107 
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The Xpert HPV assay tests for 14 hrHPV types, including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 108 
66, and 68. Cytology was prepared by spreading collected cervical cells from a Cervex-brush onto a glass 109 
slide and fixing with a spray fixative at the collection site. Cytology was sent to the National Health 110 
Laboratory for processing and pathologist evaluation and reported using the revised Bethesda 111 
classification. 31  Abnormal lower genital tract cytology was evaluated at two thresholds: abnormal 112 
squamous cells of undetermined significance (ASC-US) or worse, and high-grade squamous intraepithelial 113 
lesion (HSIL) or worse.  114 
Because there are no clinical guidelines for management of positive hrHPV results in Botswana, we also 115 
collected cytology at the time of hrHPV sample collection to ensure that all participants were screened 116 
according to current cervical cancer screening guidelines in Botswana. We referred participants who tested 117 
negative for hrHPV to colposcopy if they had a study cytology of HSIL or had a prior abnormal cytology 118 
result and study cytology result of ASC-US or worse (≥ASC-US) in accordance with current Botswana 119 
National Cervical Cancer Prevention Programme algorithms. We referred all participants who tested 120 
positive for any hrHPV type to VIA and colposcopy, regardless of their cytology result. At the time of the 121 
colposcopy visit, participants underwent a speculum examination of the cervix with both VIA and 122 
colposcopy performed by providers who were blinded to the HPV test results and cytology results. VIA 123 
was performed by a trained nurse midwife who had participated in the Botswana Ministry of Health and 124 
Wellness national VIA training program and was experienced in performing VIA in the clinical setting. 125 
Visual assessment was performed after applying 5% acetic acid to the cervix using a cotton swab and 126 
findings were categorized as normal, abnormal with recommendation for cryotherapy, or abnormal with 127 
recommendation for loop electrosurgical excision procedure (LEEP). In the analysis, we considered lesions 128 
recommended for cryotherapy as “low-grade” and lesions recommended for LEEP as “high-grade”. 129 
Subsequently, a gynecologist blinded to the VIA assessment performed colposcopy and normal, low-grade 130 
or high-grade impression was recorded. All participants had a biopsy collected at the time of colposcopy. 131 
If there was a visible lesion, a punch biopsy or LEEP was performed according to current best practice in 132 
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Botswana. If no lesion was visible, a small endocervical excision or an endocervical curettage was 133 
performed. All women with cervical intraepithelial neoplasia ≥ CIN2 (CIN2+) on biopsy or endocervical 134 
curettage were referred for an excisional procedure. Women with histopathology showing CIN3 with 135 
microinvasion or invasive cervical cancer were referred to gynecologic providers for further assessment 136 
and treatment.   137 
The primary outcome was performance of two-stage cervical cancer screening algorithms in detecting high 138 
grade cervical dysplasia. We defined high-grade cervical dysplasia as a colposcopy result of cervical 139 
intraepithelial neoplasia grade 2 or higher (CIN2+). Using histopathology collected at time of colposcopy 140 
as the gold standard, we calculated the sensitivity, specificity, positive predictive value (PPV) negative 141 
predictive value (NPV), and likelihood ratios (LR) to detect high-grade cervical dysplasia for 1) cytology 142 
following a positive hrHPV test, 2) VIA impression following a positive hrHPV test and 3) colposcopy 143 
impression following a positive hrHPV test. For each two-stage screening strategy, we evaluated test 144 
performance at two cutoffs. For cytology, we evaluated cut-offs of ASC-US and HSIL. For VIA and 145 
colposcopy, we evaluated cut-offs of low-grade and high-grade impressions. In addition, we repeated this 146 
analysis stratified by hrHPV type (16/18/45 and other hrHPV). 147 
Data were entered into a REDCap electronic database by a designated research assistant and accuracy of 148 
data entry were verified by the study nurse and principal investigator. Descriptive statistics are presented 149 
as median with interquartile range or proportion. We compared categorical variables with the chi-square 150 
or Fisher’s exact test and continuous variables with the Wilcoxon rank sum test.  We considered two-151 
sided p values <0.05 statistically significant and used SAS 9.4 (SAS Institute, Cary, North Carolina) for 152 
analyses.   153 
The goal of a two-stage algorithm to detect high-grade cervical dysplasia is to increase PPV while 154 
maintaining sensitivity and specificity. In a prior cervical cancer screening study among a population of 155 
women with a relatively high HIV prevalence, the PPV of a hrHPV positive test for high-grade cervical 156 
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dysplasia was 24% (Denny, 2000). Our sample size calculation was targeted to detect an improvement in 157 
PPV from 24% for hrHPV testing alone to 49% for the two-stage algorithms. Assuming a two-sided alpha 158 
of 0.05, a sample size of 81 participants with hrHPV was needed to yield 80% power to detect the 159 
specified difference. Based on preliminary data from a recent study of women living with HIV in 160 
Botswana, we assumed hrHPV-positivity would be 30% (unpublished data). Thus, we needed to enroll 161 
270 participants with HIV to yield 81 who would be hrHPV positive. To allow for 10% loss to follow-up 162 
between the primary hrHPV testing and colposcopy we aimed to enroll at least 300 participants. 163 
 164 
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Results 166 
We recruited participants from April to July 2018, and all follow-up colposcopy visits were completed by 167 
August 2018. Of the 312 women living with HIV enrolled, 12 were lost to follow-up, deemed ineligible or 168 
withdrawn before cervical samples were collected at the first study visit, leaving 300 (96%) who underwent 169 
hrHPV testing and cytology collection. Of those participants, 88 (29%) had a positive hrHPV result. Among 170 
those 88 who were hrHPV positive, we did not have colposcopy results for 6 (3 were lost to follow-up, 1 171 
withdrew, 1 became ineligible due to pregnancy, and 1 biopsy specimen was lost in the laboratory) and had 172 
histopathology results from colposcopy for 82 women for this analysis. Additionally, two participants who 173 
were hrHPV-negative underwent colposcopy for cytology of HSIL (Figure 1). 174 
Baseline characteristics were similar among women who tested positive and negative for hrHPV (Table 1). 175 
The majority of women reported having undergone prior cervical cancer screening (95%). There were no 176 
differences between groups in prior abnormal screening results or cervical excisional procedures. Only 5 177 
women had a recent CD4 count of < 200/µL, and all of the participants were taking antiretroviral therapy. 178 
Only two women reported a history of smoking, and both tested negative for all hrHPV types. 179 
Of the 88 (29%) women who were positive for any hrHPV type, 15 of the 300 screened had HPV 16 180 
(prevalence 5%); 21 of the 300 screened had HPV 18/45 (prevalence 7%); and 66 of the 300 screened had 181 
other hrHPV types (prevalence 22%). Among the 82 women with a positive hrHPV test who had 182 
histopathology results, 29 (35%) had CIN2+ (Table 2). The prevalence of CIN2+ by hrHPV type was 183 
31%, 21%, and 43% for HPV 16, HPV 18/45, and other hrHPV types, respectively. Among the 11 184 
participants co-infected with multiple hrHPV types, the prevalence of CIN2+ was 45%. 185 
We compared the performance of the two-stage cervical cancer screening algorithms. hrHPV followed by 186 
colposcopy impression had a sensitivity of 83%, specificity of 49%, PPV of 47%, LR+ of +1.6 and LR- 187 
of -0.4. hrHPV testing followed by VIA resulted in a reduced sensitivity of 59%, specificity of 49%, PPV 188 
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of 39%, LR+ of +1.2 and LR- of -0.8 at the low cut-off point of “low-grade impression”. hrHPV testing 189 
followed by cytology also resulted in a reduced sensitivity of 62%, specificity of 77%, PPV of 60%, LR+ 190 
of +2.7 and LR- of -0.5 at the ASC-US threshold (Table 3). Triaging hrHPV positive women with 191 
colposcopy impression, VIA and cytology missed CIN2+ diagnoses in 5, 12, and 11 women in our cohort, 192 
respectively. Evaluation of the two-stage algorithms stratified by HPV 16/18/45 versus other hrHPV 193 
types did not improve the performance of any algorithm (Table 4). 194 
Four women had histopathology results of cancer or microinvasive CIN 3. One of these women had 195 
HPV18/45 and the other three had other hrHPV types. All four had a cytology result of HSIL. Three had 196 
low-grade impressions on both VIA and colposcopy, while one had a high-grade impression on both VIA 197 
and colposcopy. 198 
Discussion:  199 
Primary hrHPV testing followed by colposcopy was the most sensitive two-stage algorithm for cervical 200 
cancer screening among women living with HIV in Botswana. Both VIA and cytology as second-stage 201 
screening methods had unacceptably low sensitivity, missing approximately one-third of women with 202 
high-grade cervical lesions. Triaging hrHPV positive results with VIA or cytology eliminated the benefit 203 
of the high sensitivity that primary hrHPV testing provides. Further, triaging of hrHPV positive results 204 
based on type did not improve the performance of any two-stage algorithm.  205 
One third of women in our study with positive hrHPV primary screening had high-grade cervical disease, 206 
which is a higher proportion than found in other populations living with HIV.32 Our population also had a 207 
higher prevalence of high-grade dysplasia among women with other hrHPV compared to women with 208 
HPV 16 or 18/45. This is consistent with prior studies in Botswana that showed heterogeneous HPV types 209 
associated with high-grade precancerous cervical lesions among women living with HIV (16, 18, 35, 58, 210 
and 61) and a lower prevalence of HPV 16 and 18 positivity in cervical cancer specimens.33,34,35 This 211 
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cross-sectional data does not support triaging strategies based on hrHPV type, as may be considered in 212 
other African settings.36   213 
Primary hrHPV testing followed by colposcopy results in a high number of referrals for colposcopy, 214 
presenting challenges in resource-limited settings.37  Guidelines for low- and middle-income countries have 215 
presumed that scaling up colposcopy is not feasible.38,39 Recent trends in cervical cancer screening in the 216 
region have focused on visual inspection strategies as opposed to colposcopy training. 40  However, 217 
consideration of available data to plan effective screening programs is vital. Our findings support concerns 218 
raised in prior studies that VIA and cytology triaging of women with hrHPV may have variable or low 219 
sensitivity, particularly in women living with HIV, and that referral to colposcopy may be a better 220 
alternative.41,42,43,44 Building on the infrastructure that visual inspection has developed may facilitate roll-221 
out of colposcopy, if coupled with the training of nurses and general practice providers in the region. In 222 
Botswana, for instance, the VIA programming has equipped a number of facilities with capability to 223 
perform LEEP, and many LEEP sites have colposcopes not currently in use. If rapid hrHPV testing were 224 
available in the future, same-day triage with colposcopy and treatment at these sites would be feasible. 225 
This study highlights the acute need to improve screening for cervical cancer and raises concern about the 226 
frequency of screening in women living with HIV in low- and middle-income countries. Current national 227 
strategy in Botswana recommends screening with cytology or VIA in women living with HIV every three 228 
years. While many of the participants had been screened before (over 90%), only 11% of women reported 229 
a prior abnormal result and 2-3% reported a prior excisional procedure. Our high prevalence of high-230 
grade pre-invasive cervical disease supports the need for frequent screening to ensure diagnosis of disease 231 
prior to progression to malignancy. In addition to high rates of pre-invasive cervical disease, the rate of 232 
detection of cervical cancer in our screening cohort was relatively high at 2%. This included 3 women 233 
enrolled but immediately referred for suspicion for clinical stage IB cervical cancer on examination and 4 234 
women with histopathology concerning for Stage IA cervical cancer (cervical cancer or microinvasive 235 
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CIN3). This rate was similar to another screening cohort in Zambia where 6 of 200 (3%) women living 236 
with HIV had invasive cervical cancers detected at the time of screening, but higher than other settings.45 237 
In a large cervical cancer screening cohort of 79,506 women in India, 238 (0.3%) invasive cervical 238 
cancers were detected (Sankaranarayanan, 2009). In a cervical cancer screening cohort of 1128 women 239 
living with HIV in India, 5 (0.4%) invasive cervical cancers were detected. 46  240 
We found lower rates of hrHPV prevalence among women living with HIV than reported in the literature, 241 
which may highlight the improvement in HIV management over time with higher antiretroviral therapy 242 
utilization and viral suppression.47,48 Botswana has had continuous access to antiretroviral therapy in the 243 
public sector since 2002, with initiation of antiretroviral therapy at graduated CD4 counts over time 244 
(initially 200 then 350) until a test-and-treat policy was initiated in 2016. Demographic differences in 245 
study populations may also contribute to this difference. Our study had a higher median age than in 246 
studies conducted in the United States, Kenya and Brazil. Additionally, the population in New York had 247 
higher risk behaviors, as indicated by high rates of smoking and on-going intravenous drug use.49 The 248 
study population in Brazil was pregnant which may have resulted in increased immunosuppression and 249 
higher hrHPV detection rates.50 Rates of hrHPV prevalence among women living with HIV in the region 250 
generally range from 47-57%, however, the prevalence is lower in women aged 40-49.51,52 In a similarly-251 
aged cohort of women in Zambia, where 90% of participants were on antiretrovirals and only 77% virally 252 
suppressed, hrHPV positivity was 47% (Chibwesha, 2016). On-going evaluation of hrHPV rates in 253 
women living with HIV in the modern antiretroviral therapy are necessary to understand if our findings 254 
are generalizable. 255 
Our study has limitations. Our confidence intervals are wide around sensitivity, specificity, PPV and NPV 256 
as a result of our relatively small sample size. Further, research in larger populations will help to clarify if 257 
the difference in performance detected in this study is significant. The cohort was recruited from an HIV 258 
treatment center, which may represent a unique population of health-seeking individuals and may not be 259 
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representative of a broader population.  Ease of communication and follow-up of abnormal results may 260 
not therefore be replicated in a larger population. However, we found many women were not only 261 
reachable, but proactively followed-up their results, indicating that improved education about cervical 262 
cancer may reduce loss to follow-up and maximize dissemination of results. While the goal of this study 263 
was to evaluate screening algorithms that would be possible with pathology services currently available, 264 
external validation of cytology and histopathology specimens was not performed and thus accuracy 265 
compared to an expert gynecologic cytopathologist and pathologist was not evaluated. History of cervical 266 
cancer screening is primarily self-reported with limited ability to confirm results in the electronic medical 267 
record. In regards to study design, the effect of co-infection with multiple hrHPV types could not be 268 
assessed because the study sample was not sufficiently powered for this subgroup. Finally, one VIA nurse 269 
and colposcopist conducted the evaluations; therefore, performance of these tests may not be 270 
generalizable.  271 
Follow-up of this cohort is currently underway to evaluate the best interval and modality for longitudinal 272 
screening. Further research on the performance of technology-based cervical cancer screening methods 273 
compared to current available methods in low- and middle-income countries is also being planned in a 274 
larger population. Balancing the cost of these strategies with clinical effectiveness is essential and a cost-275 
effectiveness evaluation of these strategies in Botswana is being explored. Finally, regional adoption of a 276 
test-and-treat policy for HIV may continue to impact cervical cancer rates in the long-term as long-277 
standing antiretroviral therapy use and initiation of treatment at higher CD4 levels may reduce incidence 278 
of cervical dysplasia, progression of dysplasia, and increase the likelihood of CIN regression.53 On-going 279 
research in our population living with HIV is essential to understand this impact. 280 
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n = 300* 
hrHPV 
positive 
n = 88 
hrHPV 
negative 
n = 212 
p 
Age, years [interquartile range] 46 [42-52] 44 [40-51] 47 [42-52] 0.05 
Education    0.40 
 ≤Primary    94 (31) 24 (27)   70 (33)  
Formatted: Indent: Left:  0 cm, Hanging:  0.63 cm
HPV 2-stage cervical screening in HIV+  
 
 ≥Secondary 206 (69) 64 (73) 142 (67)  
Employed 197 (66) 63 (72) 134 (63) 0.21 
Marital status    0.85 
 Single 215 (72) 61 (69) 154 (72)  
 Married   55 (18) 18 (20)   37 (17)  
 Divorced   12 (4) 3 (3)     9 (4)  
 Widowed   18 (6) 6 (7)   12 (6)  
Parity$    0.15 
      0   11 (4) 5 (6) 6 (3)  
      1-3 199 (66) 58 (66) 141 (67)  
      ≥4   75 (25) 24 (27) 51 (24)  
Sexual partners    0.83 
     1-5 186 (62) 55 (63) 131 (62)  
     ≥6 100 (33) 28 (32)   72 (34)  
    Missing   14 (5) 5 (6)     9 (4)  
Postmenopausal 106 (35) 27 (31)   79 (38) 0.38 
CD4 Count (per µL)    0.63 
      <200     5 (2)   2 (2)     3 (1)  
200-500   83 (28) 27 (31)   56 (26)  
>500 212 (71) 59 (67) 153 (72)  
Detectable viral load   11 (4)   6 (7)     5 (2) 0.12 
Currently on aAntiretroviral 
therapyRT 
300 (100) 88 (100) 213 (100) -- 
Length of time on antiretroviral 
therapyART,  
years [interquartile range] 
14 [11 – 15] 14 [9 – 15] 14 [12 – 15] 0.09 
History of cervical cancer screening     
Yes 285 (95) 79 (90) 206 (97) 0.02 
    Pap ≥ASC-US   27 (9) 11 (14) 
 
  16 (8) 0.44 
           VIA positive   3 (1) 1 (1) 
 
  2 (1) 1.0 
History of cervical excisional 
procedure 
6 (2) 3 (3) 3 (1) 0.18 
*All table entries are number of study subjects (%) unless otherwise noted  
$Data available for 285 participants 
ART: antiretroviral therapy; ASC-US: abnormal squamous cells of undetermined significance; VIA: visual 





Table 2: Prevalence of CIN2+ (per 100 women living with HIV) who tested positive for high-risk 
HPV and underwent colposcopy 











Any high-risk HPV type 82 29 35% [25 – 47] 
 




13 4  31% [9 – 61]  
HPV 18/45*  
 
19 4         21% [6 – 46] 
Other high-risk HPV type* 
  
61 26  43% [30 – 56] 
>1 high-risk HPV type 11 5 45% [17 – 77] 
 
*Infection with these sub-types is not mutually exclusive 
CIN2+: cervical intraepithelial neoplasia grade 2 or higher 
 
 
Table 3: Performance of two-stage screening in detecting CIN2+ among women living with HIV 
who tested positive for high-risk HPV and underwent colposcopy  
 
Two-stage screen using 
different cut-offs 

































+ 2.7 [1.1 4.3] 
-0.5 [0.2-0.7] 




























+ 1.2 [0.7–1.6] 












































CIN2+: cervical intraepithelial neoplasia grade 2 or higher; CI: confidence interval; PPV: positive predictive 
value; NPV: negative predictive value; NILM:  negative for intraepithelial lesion or malignancy; ASC-US: abnormal 






Table 4: Performance of two-stage screening in detecting CIN2+ among women living with HIV who tested positive for 
high-risk HPV and underwent colposcopy stratified by HPV type 
Study Arm CIN 2+ 
(n) 



















     NILM 3 17 -- -- -- -- 
≥ ASC-US 5 7 63 (24 – 91) 71 (49 – 87) 42 (15 – 72) 85 (62 – 97) 
≥ HSIL   3 2 38 (9 – 76) 92 (73 – 99) 60 (15 – 95) 81 (62 – 94) 
Other hrHPV  
     NILM 9 26 -- -- -- -- 
≥ ASC-US 17 9 65 (44 – 83) 74 (57 – 88) 65 (44 – 83) 74 (57 – 88) 




    Normal  4 15 -- -- -- -- 
≥ low-grade 
impression 
4 9 50 (16 – 84) 63 (41 – 81) 31 (9 – 61) 79 (54 – 64) 
≥ high-grade 
impression  
1 1 13 (0 – 53) 96 (79 – 100) 50 (1 – 99) 77 (58 – 90) 
Other hrHPV 
Normal 10 14 -- -- -- -- 
≥ low-grade 
impression 
16 21 62 (41 – 80) 40 (24 – 58) 43 (27 – 61) 58 (37 – 78) 
≥ high-grade 
impression  








88100 (47 – 
100) 
42 (22 – 63) 33 (15 – 57) 91 (59 – 100) 
≥ high-grade 
impression  
2 3 25 (3 – 65) 88 (68 – 97) 78 (58 – 91) 81 (62 – 94) 
Other hrHPV 
    Normal  4 18 -- -- -- -- 
≥ low-grade 
impression 
22 17 85 (65 – 96) 51 (34 – 69) 56 (40 – 72) 82 (60 – 95) 
≥ high-grade 
impression  
4 3 15 (4 – 35) 91 (77 – 98) 57 (18 – 90) 59 (45 – 72) 
 
